Insider Purchases: Inside the Buy

Tag: Pancreatic Cancer

Illustration showing advanced cancer diagnostics and DNA science balanced against financial risk, representing Mainz Biomed’s promising technology and high-risk biotech investment profile.

Insider Buys Shares of Mainz Biomed: Promising Science, Precarious Finances

Mainz Biomed’s cancer-screening science is compelling — and an insider just bought big. But with heavy losses, dilution risk, and a going-concern warning, MYNZ is a biotech moonshot best approached with extreme caution.

Read entire article

Tags: 10% owner buying, Biotech Stocks, buy or sell MYNZ, Colorectal Cancer, Early Cancer Detection, featured-insiders, funanc1al edge, funanc1al humor, funanc1al investing, FUNstock Index, Going Concern, High Risk High Reward, hub-insiders, hub-overseas, Insider Buying, Mainz Biomed, Microcap Biotech, MYNZ, Pancreatic Cancer, risks buying mynz, Speculative Stocks, why buy mynz
Digital illustration of a cancer cell being zapped by electric fields, symbolizing Novocure’s Tumor Treating Fields and stock rebound hopes.”

Novocure (NVCR): From Electric Fields to Fighting Cancer — and Maybe Lifting Portfolios?

Novocure is zapping cancer cells with Tumor Treating Fields — and maybe giving investors a shock of opportunity. With insiders and institutions piling in, can NVCR rebound 94% from its crash? ⚡📈

 

Read entire article

Tags: Ashley Cordova, Biotech Investing, BiotechGrowth, CEO Ashley Cordova, CEO Buys, CEO Conviction, CEO insider buying, CEO Stock Purchase, CEOBuyIn, CEOConfidence, CFO Bought Shares, CFO Insider Buying, CFOBuyIn, Funanc1al Humor, funanc1al investing, Funanc1al Stocks, glioblastoma, high-risk biotech, high-risk high-reward biotech, insider buying, institutional investors, Novocure, NVCR stock, oncology stocks, pancreatic cancer, tumor treating fields